Silver Book Fact

Over 6 years, flu vaccine prevented ~13 million cases

Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.

Kostova, Deliana, Carrie Reed, Lyn Finelli, Po-Yung Cheng, Paul M. Gargiullo, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PLoS ONE. 2013; 8(6): e66312. doi:10.1371/journal.pone.0066312. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066312

Reference

Title
Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011
Publication
PLoS ONE
Publication Date
2013
Authors
Kostova, Deliana, Carrie Reed, Lyn Finelli, Po-Yung Cheng, Paul M. Gargiullo, et al.
Volume & Issue
Volume 8, Issue 6
Pages
e66312. doi:10.1371/journal.pone.0066312.
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Eradication of infectious diseases from vaccination
    Spanning more than 200 years of research and development, 10 infectious diseases have been at least 90 percent eradicated in the United States thanks to vaccines.  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.